For severe cases, the first dose is usually 1,000 mcg given intramuscularly every day or every other day for a week or two
(wada-ama.org) The clinical bottom line (Meto-style) AOD-9604 is a legitimate fat-metabolism peptide in the sense that it has: a plausible mechanism, preclinical support, and a history of controlled human trials
NuRev Peptides does not make claims regarding outcomes, efficacy, or safety related to this product
This allows the vial to be used for multiple withdrawals over a limited period when handled properly
Amgen, the pharmaceutical company that produces Enbrel in the United States, still has patent protection over the drug, meaning other companies cannot yet make biosimilar versions of the medication that tend to be less expensive. There is no Enbrel biosimilar (comparable to a generic) yet